Posted by Michael Wonder on 27 Dec 2023
Bimzelx (bimekizumab) receives approval in Japan for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis
27 December 2023 - The extended approval for bimekizumab in Japan follows its first approval in January 2022 for plaque psoriasis, generalised pustular psoriasis, and psoriatic erythroderma.
UCB today announced that the Japanese Ministry of Health, Labour and Welfare has approved Bimzelx (bimekizumab) for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis who are not sufficiently responding to existing treatments.
